Table 1.
Natural product-derived antimicrobial compounds under investigationa
| Name (synonym) | Class (lead compound) | Developer |
|---|---|---|
| NVP LBM 415 (NVP PDF 713) | Peptide deformylase inhibitor (actinonin) | Novartis |
| Rifalazil (ABI-1648, KRM-1648) | Ansamycin (rifamycin B) | ActivBiotics |
| Ceftobripole medocaril (BAL-5788) | β-lactam-cephalosporin | Basilea and J & J |
| PPI-0903 (TAK-599) | β-lactam-cephalosporin | Cerexa |
| RWJ-442831 | β-lactam-cephalosporin | J & J |
| CS-023 (R1558) | β-lactam-cephalosporin | Roche/Sankyo |
| Tebipenem pivoxil (ME1211) | β-lactam-carbapenem | Meiji Seika Kaisha |
| ME1036 (CP5069) | β-lactam-carbapenem | Meiji Seika Kaisha |
| Faropenem daloxate | β-lactam-penem | Replidyne |
| Dalbavancin | glycopeptide (A40926) | Vicuron |
| Telavancin (TD-6424) | glycopeptide (vancomycin) | Theravance |
| Cethromycin | macrolide (erythromycin) | Advanced Life Sciences |
| EP-013420 | macrolide (erythromycin) | Enanta/Shionogi |
| Pleuromutilin derivative (565154) | new (pleuromutilin) | GlaxoSmithKline |
| Ramoplanin | new (ramoplanin) | Oscient |
| NXL103 (XRP2868)-RPR132552A and RPR202698 | streptogramin | Novexel |
| PTK0796 | tetracycline | Paratek |
| Tiacumicin B (PAR-101, OPT-80) | new (tiacumicin) | Par |
a
14/19 are derivates of known drugs. only NVP LBM-415, pleuromutilin derivative (565154), ramoplanin, and tiacumicin B are not related to drugs previously marketed for human use.